S
Sekhar Surapaneni
Researcher at Bristol-Myers Squibb
Publications - 7
Citations - 70
Sekhar Surapaneni is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Metabolite & Active metabolite. The author has an hindex of 2, co-authored 7 publications receiving 12 citations.
Papers
More filters
Journal ArticleDOI
Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
Sekhar Surapaneni,Usha Yerramilli,April Bai,Deepak Dalvie,Jennifer Brooks,Xiaomin Wang,Julie V. Selkirk,Yingzhuo Grace Yan,Peijin Zhang,Richard Hargreaves,Gondi Kumar,Maria Palmisano,Jonathan Q. Tran +12 more
TL;DR: Ozanimod was extensively metabolized, with 14 metabolites identified, including two major active metabolites (CC112273 and CC1084037) and one major inactive metabolite (RP101124) in circulation as discussed by the authors.
Journal ArticleDOI
Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Allison Gaudy,Christian Atsriku,Ying Ye,Kimberly MacGorman,Liangang Liu,Yongjun Xue,Sekhar Surapaneni,Maria Palmisano +7 more
TL;DR: Caution should be taken when coadministering iberdomide with strong CYP3A inducers is not advised, and exploratory assessment of metabolite M12 concentrations demonstrated that CYP 3A is responsible for M12 formation.
Journal ArticleDOI
Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib
TL;DR: The physiologically based pharmacokinetic (PBPK) model of fedratinib facilitated drug development by identifying DDI potential, optimizing clinical study designs, supporting waivers for clinical studies, and informing drug label claims.
Journal ArticleDOI
Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects
Ken Ogasawara,Christine Xu,Vanaja Kanamaluru,Nicholas Siebers,Sekhar Surapaneni,Laurence Ridoux,Maria Palmisano,Gopal Krishna +7 more
TL;DR: Fedratinib derived radioactivity was primarily excreted in feces following a single oral dose of radiolabeled fedrat inib to healthy subjects, indicating limited distribution of fedratInib and/or its metabolites into red blood cells.
Journal ArticleDOI
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Ken Ogasawara,Rebecca N. Wood-Horrall,Mark Thomas,Michael Thomas,Liangang Liu,Mary Liu,Yongjun Xue,Sekhar Surapaneni,Leonidas N Carayannopoulos,Simon Zhou,Maria Palmisano,Gopal Krishna +11 more
TL;DR: In this paper, the authors evaluated the influence of fedratinib on the pharmacokinetics of digoxin (P-gp substrate), rosuvastatin (OATP1B1/1B3 and BCRP substrate), and metformin (OCT2 and MATE1/2-K substrate).